Lu Kang Pharmaceutical announced that the company plans to renew the “Trademark License Agreement” with the controlling shareholder Hualu Group, which constitutes a related transaction. The deal has already been reviewed at the 11th meeting of the 11th board of directors. Related directors Zhang Chengyong and Liu Chengtong avoided voting, did not require review by a shareholders' meeting, and did not constitute a major asset restructuring. According to the agreement, the annual usage fee is 13.45 million yuan and is valid for 3 years. In the past 12 months, the amount of related transactions between the company and Hualu Group was 7.6 million yuan. Hualu Group directly and indirectly holds 23.82% of the company's shares.

Lu Kang Pharmaceutical announced that the company plans to renew the “Trademark License Agreement” with the controlling shareholder Hualu Group, which constitutes a related transaction. The deal has already been reviewed at the 11th meeting of the 11th board of directors. Related directors Zhang Chengyong and Liu Chengtong avoided voting, did not require review by a shareholders' meeting, and did not constitute a major asset restructuring. According to the agreement, the annual usage fee is 13.45 million yuan and is valid for 3 years. In the past 12 months, the amount of related transactions between the company and Hualu Group was 7.6 million yuan. Hualu Group directly and indirectly holds 23.82% of the company's shares.